Plasminogen Activator Inhibitor-1-Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype.

Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1-positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients.
Competing Interests: This project was supported by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario and the Canadian Foundation of Innovation. Dr Jung was funded by the Vanier Canadian Institutes of Health Research Canada Graduate Scholarship for his graduate studies. Dr Duchez was supported by the Cardiac Endowment Fund at the University of Ottawa Heart Institute. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(© 2022 The Authors.)